Medpace (MEDP) competitors & alternatives
Health Care · NASDAQ
Medpace (MEDP)'s top competitors and alternatives — its most similar public companies — include IQVIA (IQV), Charles River Laboratories (CRL), ORIC PHARMACEUTICALS INC (ORIC), BIOAGE LABS INC (BIOA), CAMP4 THERAPEUTICS CORP (CAMP), FORTREA HOLDINGS INC (FTRE), Labcorp (LH), MAPLIGHT THERAPEUTICS INC (MPLT), SIMULATIONS PLUS INC (SLP), TAYSHA GENE THERAPIES INC (TSHA), Veeva Systems (VEEV) and ENANTA PHARMACEUTICALS INC (ENTA). These are Medpace's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top MEDP competitors & alternatives
-
IQVIAIQVHealth Care
IQVIA is a global clinical research and healthcare intelligence platform that powers drug development and commercialization with AI-driven insights from 1.2…
$198.52 (as of 2026-07-22) · market cap $33.2B
-
Charles River LaboratoriesCRLHealth Care
A global contract research organization providing non-clinical drug development services, research models, and manufacturing solutions across discovery, safety…
$218.70 (as of 2026-07-22) · market cap $10.6B
-
ORIC PHARMACEUTICALS INCORICHealth Care
ORIC Pharmaceuticals is a clinical-stage oncology company developing targeted therapies for hard-to-treat cancers through precision medicine approaches.
$10.75 (as of 2026-07-22) · market cap $1.1B
-
BIOAGE LABS INCBIOAHealth Care
Clinical-stage biotech targeting aging biology to develop novel small-molecule therapeutics for metabolic and cardiovascular diseases, led by brain-penetrant…
$21.94 (as of 2026-07-22) · market cap $975M
-
CAMP4 THERAPEUTICS CORPCAMPHealth Care
CAMP4 is pioneering a novel RNA-targeting platform to upregulate deficient genes in rare genetic diseases, starting with SYNGAP1-related developmental epilepsy.
$3.11 (as of 2026-07-22) · market cap $166M
-
FORTREA HOLDINGS INCFTREHealth Care
Fortrea is a global contract research organization that accelerates the delivery of life-changing treatments by providing flexible, science-driven clinical…
$18.49 (as of 2026-07-22) · market cap $1.7B
-
LabcorpLHHealth Care
A global diagnostics and drug development laboratory leader that performs 750+ million clinical tests annually and supports 85% of new FDA-approved drugs…
$281.46 (as of 2026-07-22) · market cap $23.1B
-
MAPLIGHT THERAPEUTICS INCMPLTHealth Care
MapLight Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel, targeted treatments for central nervous…
$35.31 (as of 2026-07-22) · market cap $1.6B
-
SIMULATIONS PLUS INCSLPHealth Care
Simulations Plus provides advanced modeling and simulation software and services to accelerate drug discovery and clinical development for the life sciences…
$18.25 (as of 2026-07-22) · market cap $368M
-
TAYSHA GENE THERAPIES INCTSHAHealth Care
Taysha Gene Therapies is a clinical-stage biotech company pioneering AAV-based gene therapies to treat severe, rare monogenic diseases of the central nervous…
$5.66 (as of 2026-07-22) · market cap $1.8B
-
Veeva SystemsVEEVHealth Care
Veeva is the dominant cloud software and data platform powering the global life sciences industry from drug development through commercialization, with…
$184.55 (as of 2026-07-22) · market cap $29.8B
-
ENANTA PHARMACEUTICALS INCENTAHealth Care
A biotechnology company leveraging small molecule discovery to treat viral and liver diseases, supported by recurring HCV royalty streams.
$13.06 (as of 2026-07-22) · market cap $390M
Not quite? Describe exactly what you want →
Peers are Medpace's closest public companies by shared sub-industry, sector and business themes. See the full profile: Medpace (MEDP).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.